ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2021; 11(14):7128-7129. doi:10.7150/thno.62534 This issue Cite
Erratum
CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum
Wenzhi Shen1,2, 
, Xiaoyuan Zhang1,2, Jiaping Tang3, Zhixin Zhang4, Renle Du5, Dehong Luo6, Xiaoran Liu1, Yong Xia1, Yanping Li1, Shanshan Wang1, Siyuan Yan1, Wancai Yang1, Rong Xiang5, Na Luo3, Yunping Luo7, Jianjun Li2
1. Dept. of Pathology and Institute of Precision Medicine, Jining Medical University, Jining 272067, China.
2. Institute of Breast Research, Jining Medical University, Jining 272067, China.
3. Dept. of Anatomy and Histology, School of Medicine, Nankai University, Tianjin 300071, China.
4. Dept. of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical University, Jining 272029, China.
5. Dept. of Immunology, School of Medicine, Nankai University, Tianjin 300071, China.
6. The First People's Hospital of Zunyi, Zunyi, 563002, China.
7. Dept. of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China.
Citation:
Shen W, Zhang X, Tang J, Zhang Z, Du R, Luo D, Liu X, Xia Y, Li Y, Wang S, Yan S, Yang W, Xiang R, Luo N, Luo Y, Li J. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum. Theranostics 2021; 11(14):7128-7129. doi:10.7150/thno.62534. https://www.thno.org/v11p7128.htm
Other stylesCorrected-article in Theranostics, Volume 11, 2297
In our article [1], there were misplaced images in Figure 7E and Figure 8D, respectively. The corrected version is provided here:
Figure 7
E. Immunohistochemistry staining of CCR2, p-AKT, p-GSK3β, β-catenin and OCT4 in each group tumors was performed. Representative images were shown. Scale bars: 50 μm.
Figure 8
D. The representative luciferase images showing 231-luci tumors of each group on Day 12 (before XAV939 administration) and Day 60 (after XAV939 administration).
The correction made in this erratum does not affect the original conclusions. The authors apologize for any inconvenience or misunderstanding that this error may have caused.
References
1. Shen WZ, Zhang XY, Tang JP, Zhang ZX, Du RL, Luo DH. et al. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis. Theranostics. 2021;11:2297-317 doi:10.7150/thno.51000
Author contact
Corresponding author: Wenzhi Shen, Dept. of Pathology and Institute of Precision Medicine & Institute of Breast Research, Jining Medical University, Jining 272067, China. E-mail: shenwenzhijnmc.edu.cn
Published 2021-5-15
Citation styles
APA
Shen, W., Zhang, X., Tang, J., Zhang, Z., Du, R., Luo, D., Liu, X., Xia, Y., Li, Y., Wang, S., Yan, S., Yang, W., Xiang, R., Luo, N., Luo, Y., Li, J. (2021). CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum. Theranostics, 11(14), 7128-7129. https://doi.org/10.7150/thno.62534.
ACS
Shen, W.; Zhang, X.; Tang, J.; Zhang, Z.; Du, R.; Luo, D.; Liu, X.; Xia, Y.; Li, Y.; Wang, S.; Yan, S.; Yang, W.; Xiang, R.; Luo, N.; Luo, Y.; Li, J. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum. Theranostics 2021, 11 (14), 7128-7129. DOI: 10.7150/thno.62534.
NLM
Shen W, Zhang X, Tang J, Zhang Z, Du R, Luo D, Liu X, Xia Y, Li Y, Wang S, Yan S, Yang W, Xiang R, Luo N, Luo Y, Li J. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum. Theranostics 2021; 11(14):7128-7129. doi:10.7150/thno.62534. https://www.thno.org/v11p7128.htm
CSE
Shen W, Zhang X, Tang J, Zhang Z, Du R, Luo D, Liu X, Xia Y, Li Y, Wang S, Yan S, Yang W, Xiang R, Luo N, Luo Y, Li J. 2021. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum. Theranostics. 11(14):7128-7129.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.